Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Posada-de-la-Paz, Manuel"'
Autor:
Villar Hernández AR; Dystrophic Epidermolysis Bullosa Research Association ONG DEBRA España Piel de Mariposa, 29601 Marbella, Spain.; Department of Social and Organizational Psychology, Universidad Nacional de Educación a Distancia (UNED), 28040 Madrid, Spain., Molero Alonso F; Department of Social and Organizational Psychology, Universidad Nacional de Educación a Distancia (UNED), 28040 Madrid, Spain., Aguado Marín ÁJ; School of Management, New Jersey Institute of Technology, Newark, NJ 07102, USA., Posada de la Paz M; Institute of Rare Diseases Research (IIER), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Publikováno v:
International journal of environmental research and public health [Int J Environ Res Public Health] 2022 Jun 09; Vol. 19 (12). Date of Electronic Publication: 2022 Jun 09.
Autor:
Angelis A; Department of Social Policy and LSE Health, London School of Economics and Political Science, London, UK. a.n.angelis@lse.ac.uk., Kanavos P; Department of Social Policy and LSE Health, London School of Economics and Political Science, London, UK., López-Bastida J; University of Castilla-La Mancha, Talavera de la Reina, Toledo, Spain.; Red de Investigación en Servicios Sanitarios en Enfermedades Crónicas (REDISSEC), Madrid, Spain., Linertová R; Red de Investigación en Servicios Sanitarios en Enfermedades Crónicas (REDISSEC), Madrid, Spain.; Fundación Canaria de Investigación Sanitaria (FUNCANIS), Las Palmas de Gran Canaria, Spain., Oliva-Moreno J; Red de Investigación en Servicios Sanitarios en Enfermedades Crónicas (REDISSEC), Madrid, Spain.; University of Castilla-La Mancha, Toledo, Spain., Serrano-Aguilar P; Red de Investigación en Servicios Sanitarios en Enfermedades Crónicas (REDISSEC), Madrid, Spain.; Evaluation and Planning Service at Canary Islands Health Service, Santa Cruz de Tenerife, Spain., Posada-de-la-Paz M; Institute of Rare Diseases Research, ISCIII, SpainRDR and CIBERER, Madrid, Spain., Taruscio D; National Center for Rare Diseases, Istituto superiore di sanità (ISS), Rome, Italy., Schieppati A; Centro di Ricerche Cliniche per Malattie Rare Aldo e Cele Daccò, Istituto di Ricerche Farmacologiche Mario Negri, Ranica (Bergamo), Italy., Iskrov G; Institute of Rare Diseases, Plovdiv, Bulgaria.; Department of Social Medicine and Public Health, Faculty of Public Health, Medical University of Plovdiv, Plovdiv, Bulgaria., Brodszky V; Department of Health Economics, Corvinus University of Budapest, Budapest, Hungary., von der Schulenburg JM; Centre for Health Economics Research Hannover (CHERH), Leibniz Universität Hannover, Hannover, Germany., Chevreul K; URC Eco Ile de France, AP-HP, Paris, France.; Université Paris Diderot, Sorbonne Paris Cité, ECEVE, UMRS 1123, Paris, France.; INSERM, ECEVE, U1123, Paris, France., Persson U; The Swedish Institute for Health Economics, Lund, Sweden., Fattore G; Centre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy.
Publikováno v:
The European journal of health economics : HEPAC : health economics in prevention and care [Eur J Health Econ] 2016 Apr; Vol. 17 Suppl 1, pp. 31-42. Date of Electronic Publication: 2016 Apr 23.
Autor:
BURQOL-RD Research Network, Angelis, Aris, Kanavos, Panos, López-Bastida, Julio, Linertová, Renata, Oliva-Moreno, Juan, Serrano-Aguilar, Pedro, Posada-de-la-Paz, Manuel, Taruscio, Domenica, Schieppati, Arrigo, Iskrov, Georgi, Brodszky, Valentin, von der Schulenburg, Johann Matthias Graf, Chevreul, Karine, Persson, Ulf, Fattore, Giovanni
Publikováno v:
The European Journal of Health Economics, 2016 Apr 01. 17, S31-S42.
Externí odkaz:
https://www.jstor.org/stable/24774151
Autor:
Angelis, Aris, Kanavos, Panos, Lopez-Bastida, Julio, Linertova, Renata, Oliva-Moreno, Juan, Serrano-Aguilar, Pedro, Posada-De-La-Paz, Manuel, Taruscio, Domenica, Schieppati, Arrigo, Iskrov, Georgi, Brodszky, Valentin, Schulenburg, Johann-Matthias Graf Von Der, Chevreul, Karine, Persson, Ulf, Fattore, Giovanni
BACKGROUND: The aim of this study was to determine the social/economic costs and health-related quality of life (HRQOL) of patients with epidermolysis bullosa (EB) in eight EU member states. METHODS: We conducted a cross-sectional study of patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::496e3bf84b78b6d35b93762723a9fb5e